177 related articles for article (PubMed ID: 26229433)
1. The efficacy and safety of pemetrexed-based doublet therapy compared to pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer: an updated meta-analysis.
Zhong A; Xiong X; Shi M; Xu H
Drug Des Devel Ther; 2015; 9():3685-93. PubMed ID: 26229433
[TBL] [Abstract][Full Text] [Related]
2. Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomized control trials.
Huang LT; Cao R; Wang YR; Sun L; Zhang XY; Guo YJ; Zhao JZ; Zhang SL; Jing W; Song J; Han CB; Ma J
BMC Cancer; 2021 Apr; 21(1):426. PubMed ID: 33865364
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer.
Liu X; Guo Z; Su L; Zuo A; Gao M; Ji X; Lu J; Yang S; Jiang Y; Lu D
Invest New Drugs; 2024 Jun; 42(3):309-317. PubMed ID: 38700579
[TBL] [Abstract][Full Text] [Related]
4. Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Lima AB; Macedo LT; Sasse AD
PLoS One; 2011; 6(8):e22681. PubMed ID: 21829644
[TBL] [Abstract][Full Text] [Related]
5. WITHDRAWN: Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease.
Delbaldo C; Michiels S; Rolland E; Syz N; Soria JC; Le Chevalier T; Pignon JP
Cochrane Database Syst Rev; 2012 Apr; 2012(4):CD004569. PubMed ID: 22513924
[TBL] [Abstract][Full Text] [Related]
6. Overall survival benefits for combining targeted therapy as second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of published data.
Qi WX; Wang Q; Jiang YL; Sun YJ; Tang LN; He AN; Min DL; Lin F; Shen Z; Yao Y
PLoS One; 2013; 8(2):e55637. PubMed ID: 23409011
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of veliparib combined with traditional chemotherapy for treating patients with lung cancer: a comprehensive review and meta-analysis.
Zhao G; Feng E; Liu Y
PeerJ; 2023; 11():e16402. PubMed ID: 37965288
[TBL] [Abstract][Full Text] [Related]
8. Clinical analysis of anlotinib as first-line treatment for elderly patients with advanced lung adenocarcinoma without driver gene mutations.
Zhu J; Xie Q; Zhong A; Le Y
Anticancer Drugs; 2022 Jan; 33(1):e584-e589. PubMed ID: 34387607
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Addition of Antiangiogenic Agents to Taxanes-Containing Chemotherapy in Advanced Nonsmall-Cell Lung Cancer: A Meta-Analysis and Systemic Review.
Sheng J; Yang YP; Yang BJ; Zhao YY; Ma YX; Hong SD; Zhang YX; Zhao HY; Huang Y; Zhang L
Medicine (Baltimore); 2015 Aug; 94(31):e1282. PubMed ID: 26252298
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of PARP inhibitor in non-small cell lung cancer: a systematic review with meta-analysis.
Olivares-Hernández A; Roldán-Ruiz J; Miramontes-González JP; Toribio-García I; García-Hernández JL; Posado-Domínguez L; Bellido-Hernández L; Cruz-Hernández JJ; Fonseca-Sánchez E; Del Barco-Morillo E
Chin Clin Oncol; 2023 Dec; 12(6):62. PubMed ID: 38195073
[TBL] [Abstract][Full Text] [Related]
11. Complex decisions for first-line and maintenance treatment of advanced wild-type non-small cell lung cancer.
Gentzler RD; Johnson ML
Oncologist; 2015 Mar; 20(3):299-306. PubMed ID: 25660158
[TBL] [Abstract][Full Text] [Related]
12. Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review).
Zinner R; Visseren-Grul C; Spigel DR; Obasaju C
Int J Oncol; 2016 Jan; 48(1):13-27. PubMed ID: 26530033
[TBL] [Abstract][Full Text] [Related]
13. Erlotinib-based doublet targeted therapy versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis from 24 randomized controlled trials.
Gao JW; Zhan P; Qiu XY; Jin JJ; Lv TF; Song Y
Oncotarget; 2017 Sep; 8(42):73258-73270. PubMed ID: 29069867
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety profile of combining antiangiogenic agents with chemotherapy in patients with advanced malignant pleural mesothelioma: A systematic review and meta-analysis of randomized controlled trials.
Tian W; Guo Q; Fu D; Ma X; Wang R
PLoS One; 2023; 18(12):e0295745. PubMed ID: 38127857
[TBL] [Abstract][Full Text] [Related]
15. Renal failure during chemotherapy: renal biopsy for assessing subacute nephrotoxicity of pemetrexed.
Assayag M; Rouvier P; Gauthier M; Costel G; Cluzel P; Mercadal L; Deray G; Isnard Bagnis C
BMC Cancer; 2017 Nov; 17(1):770. PubMed ID: 29145816
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation.
Yoshimura N; Kudoh S; Mitsuoka S; Yoshimoto N; Oka T; Nakai T; Suzumira T; Matusura K; Tochino Y; Asai K; Kimura T; Kawaguchi T; Hirata K
Lung Cancer; 2015 Oct; 90(1):65-70. PubMed ID: 26238424
[TBL] [Abstract][Full Text] [Related]
17. The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients.
Kucharczyk T; Krawczyk P; Powrózek T; Kowalski DM; Ramlau R; Kalinka-Warzocha E; Knetki-Wróblewska M; Winiarczyk K; Krzakowski M; Milanowski J
Pathol Oncol Res; 2016 Jan; 22(1):49-56. PubMed ID: 26277606
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.
Shukuya T; Ko R; Mori K; Kato M; Yagishita S; Kanemaru R; Honma Y; Shibayama R; Koyama R; Shimada N; Takahashi K
Cancer Chemother Pharmacol; 2015 Oct; 76(4):771-6. PubMed ID: 26259641
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of pemetrexed plus platinum doublet chemotherapy as first-line treatment for advanced nonsquamous non-small-cell-lung cancer: a systematic review and meta-analysis.
Xiao HQ; Tian RH; Zhang ZH; Du KQ; Ni YM
Onco Targets Ther; 2016; 9():1471-6. PubMed ID: 27042115
[TBL] [Abstract][Full Text] [Related]
20. Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs.
Lee SJ; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2015 Nov; 90(2):261-6. PubMed ID: 26371700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
